PressNovember 16, 2023 Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp
PressNovember 16, 2023 PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
PressNovember 16, 2023 US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
PressNovember 16, 2023 Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
PressNovember 16, 2023 Filament Health Announces Third Quarter 2023 Financial Results and Operational Highlights
PressNovember 14, 2023 Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
PressNovember 14, 2023 Atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
PressNovember 13, 2023 Red Light Holland Psilocybin Microdosing Capsules Aimed to Be Distributed in Emerging Markets Pass Four Month Stability Testing by C-CREST Laboratories in Montreal, Canada
PressNovember 13, 2023 The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day
PressNovember 9, 2023 PSYC’s CEO to Moderate Panel at The Cannabis & Psychedelics Investment Summit Hosted by Kahner Global
PressNovember 9, 2023 Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
PressNovember 9, 2023 Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
PressNovember 6, 2023 Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
PressNovember 6, 2023 Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer
PressNovember 6, 2023 DEA Announces Major Increase to 2023 Production Quotas for Psilocybin, THC and Ibogaine
